Estimating the full health and economic benefits of current and future influenza vaccines

BMC Medicine

Correspondence

E. Azziz-Baumgartner¹  K. E. Lafond¹  R. Gharpure¹  V. G. Dugan¹ 

[1] Influenza Division, Centers for Disease Control and Prevention, 30307, Atlanta, GA, USA;

关键词: Influenza;    Global health;    Vaccines;    Burden of disease;    Cost-effectiveness;   

DOI  :  10.1186/s12916-023-02995-4

 received in 2023-05-01, accepted in 2023-07-20,  发布年份 2023

来源: Springer

【 摘 要 】

In the dynamic landscape of respiratory virus vaccines, it is crucial to assess the value of novel mRNA and combination influenza/COVID-19 vaccines in low- and middle-income countries. Modeling studies, such as the one conducted by Waterlow et al., provide vital information about the cost–benefit potential of these products compared to currently licensed vaccines. However, this approach only accounts for directly measured medically attended influenza-associated illnesses and has two major limitations. First, this method fails to capture the full disease burden of influenza (including non-respiratory and non-medically attended influenza illnesses), which are particularly important drivers of disease burden in infants and older adults. Second, the model does not describe the ancillary benefits of influenza vaccination such as the attenuation of severe disease, prevention of severe non-respiratory outcomes (e.g., myocardial infarctions), or reduced antibiotic use. To obtain a comprehensive understanding of the benefits of influenza vaccines, we must strive to improve the inputs for future modeling-based evaluations.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023